GlycoMimetics: Is No News Bad News?
Seeking Alpha,
Follow Summary GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia.
Follow Summary GlycoMimetics is a biotech company focusing on developing a targeted therapy for acute myeloid leukemia.
Follow Summary GlycomiMetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute…
Follow Summary GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer.
ROCKVILLE - GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action…
Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance ROCKVILLE, Md.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that important new preclinical data on the mechanism of action for its late-st…
Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance ROCKVILLE, Md.--( BUSINESS WIRE …
13:00 UTC Research shows that uproleselan is a potent antagonist of E-selectin, can break chemoresistance ROCKVILLE, Md.--…